Intravenous sub-anesthetic ketamine for perioperative analgesia

Andrew W. Gorlin, David M. Rosenfeld, Harish Ramakrishna

Research output: Contribution to journalReview articlepeer-review

64 Scopus citations

Abstract

Ketamine, an N-methyl-d-aspartate antagonist, blunts central pain sensitization at sub-anesthetic doses (0.3 mg/kg or less) and has been studied extensively as an adjunct for perioperative analgesia. At sub-anesthetic doses, ketamine has a minimal physiologic impact though it is associated with a low incidence of mild psychomimetic symptoms as well as nystagmus and double vision. Contraindications to its use do exist and due to ketamine's metabolism, caution should be exercised in patients with renal or hepatic dysfunction. Sub-anesthetic ketamine improves pain scores and reduces perioperative opioid consumption in a broad range of surgical procedures. In addition, there is evidence that ketamine may be useful in patients with opioid tolerance and for preventing chronic postsurgical pain.

Original languageEnglish (US)
Pages (from-to)160-167
Number of pages8
JournalJournal of Anaesthesiology Clinical Pharmacology
Volume32
Issue number2
DOIs
StatePublished - Apr 1 2016

Keywords

  • Ketamine
  • N-methyl-d-aspartate
  • pain

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • Pharmacology (medical)
  • Anesthesiology and Pain Medicine

Fingerprint

Dive into the research topics of 'Intravenous sub-anesthetic ketamine for perioperative analgesia'. Together they form a unique fingerprint.

Cite this